Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)

191
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
11/19/2014 11/20/2014 11/21/2014 11/24/2014 11/25/2014 Date
288.3(c) 288.3(c) 289.9(c) 288.3(c) 285.8(c) Last
1 224 539 811 043 1 566 776 953 958 1 546 287 Volume
+0.73% 0.00% +0.55% -0.55% -0.87% Change
More quotes
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
12/03Presentation
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Financials ( CHF)
Sales 2014 47 249 M
EBIT 2014 17 495 M
Net income 2014 11 781 M
Debt 2014 6 543 M
Yield 2014 2,85%
Sales 2015 49 645 M
EBIT 2015 18 837 M
Net income 2015 12 825 M
Debt 2015 650 M
Yield 2015 3,08%
PER 2014 20,76
PER 2015 18,85
EV / Sales 2014 5,38x
EV / Sales 2015 5,00x
Capitalization 247 749 M
More Financials
Latest news on ROCHE HOLDING LTD.
1d agoDJBristol-Myers, Five Prime to Collaborate on Immunotherapy
5d ago U.S. court denies Ranbaxy's bid to block launch of rival generics
11/18 Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies
11/17 Pfizer dampens Astra bid hopes with German Merck cancer deal
11/17DJROCHE : Gets U.S. Approval for Avastin Treatment of Ovarian Cancer
11/14 ROCHE : FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy t..
10/27 Weak Merck sales overshadow third quarter cost cuts
10/22 Roche to spend $3.2 billion on towering Basel base
10/22DJRoche to Spend CHF3 Billion in Research Center, Basel Headquarters
10/16 ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
10/16 New breast cancer drugs boost sales at Roche
10/15 ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF